Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Comparison of ATG to Thymoglobuline in Renal Transplantation

This study has been completed.
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland Identifier:
First received: March 12, 2009
Last updated: April 13, 2015
Last verified: April 2015
An open, multicenter, randomised, parallel group pilot study to investigate two different polyclonal rabbit immunoglobulin preparations for safety and efficacy: A comparison of ATG-Fresenius S to Thymoglobulin in prophylaxis for immunological high risk patients following renal transplantation. This non-inferiority trial shall demonstrate that ATG-Fresenius S is as efficacious as Thymoglobulin but has a better tolerance and fewer side effects.

Condition Intervention Phase
Transplantation, Kidney
Drug: ATG Fresenius
Drug: Thymoglobuline Genzyme
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open, Multicenter, Randomised, Parallel Group Pilot Study to Investigate Two Different Polyclonal Rabbit Immunoglobulin Preparations for Safety and Efficacy:A Comparison of ATG-Fresenius S to Thymoglobulin in Prophylaxis for Immunological High Risk Patients Following Renal Transplantation

Resource links provided by NLM:

Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • Adverse events [ Time Frame: Daily ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Rejection [ Time Frame: Daily ] [ Designated as safety issue: No ]
  • Graft function [ Time Frame: Daily ] [ Designated as safety issue: Yes ]
  • Patient survival [ Time Frame: Daily ] [ Designated as safety issue: Yes ]
  • Graft survival [ Time Frame: Daily ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: January 2009
Study Completion Date: February 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ATG Fresenius Drug: ATG Fresenius
Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
Active Comparator: Thymoglobuline Genzyme Drug: Thymoglobuline Genzyme
Day 0-3: 1.5 mg/kg bw/d


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Recipients, who are at least 18 years or older and have a high immunological risk defined by:

    The presence of at least one donor-specific antibody (class I and/or II) detected and specified by flow-technology (FlowPRA and single antigen beads), which are

    • For class I below the threshold of detection of a current CDC T-cell-/ and B-cell cross-match
    • For class II below the threshold of detection of a current CDC B-cell cross-match.
  2. Patient receives a renal allograft only.
  3. Female patients of child bearing age agree to maintain effective birth control practice during the study.
  4. Patient has been fully informed and has given written or independent person witnessed oral informed consent.

Exclusion Criteria:

  1. Patient is pregnant or breastfeeding.
  2. Patient has a low immunological risk constellation, defined by receiving a kidney from a HLA-identical related living donor.
  3. Patient and donor have a positive T-cell crossmatch.
  4. Patient and donor are ABO incompatible.
  5. Patient with combined transplantation.
  6. Age of donor >75 years.
  7. Cold ischemia time >40 hours.
  8. Patient has leucopenia, defined as having at transplantation less than 3000/mm3 leukocytes.
  9. Patient has thrombocytopenia, defined as having at transplantation less than 75000/mm3 thrombocytes.
  10. Patient is allergic or intolerant to ATG-Fresenius S, Thymoglobulin, steroids, Tacrolimus or MMF.
  11. EBV risk constellation (recipient EBV negative and donor EBV positive).
  12. Patient or donor is known to be HIV positive.
  13. Patient has a liver disease, defined as continuously having ASAT (SGOT) and/or ALAT (SGPT) levels greater than 3fold of the upper value of the normal range of the investigational site during the past 28 days.
  14. Patient with malignancy or history of malignancy <2 years, except non metastatic basal or squamous cell carcinoma of the skin that has been treated successfully.
  15. Patient has uncontrolled concomitant infections and/or severe diarrhea, vomiting, or active peptic ulcer.
  16. Patient is unlikely to comply with the visits schedule in the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00861536

University Hospital Basel, Transplantation Immunology and Nephrology
Basel, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Principal Investigator: Juerg Steiger, MD,Prof University Hospital Basel, Transplantation Immunology and Nephrology
  More Information

Responsible Party: University Hospital, Basel, Switzerland Identifier: NCT00861536     History of Changes
Other Study ID Numbers: 82/06 
Study First Received: March 12, 2009
Last Updated: April 13, 2015
Health Authority: Switzerland: Swissmedic

Keywords provided by University Hospital, Basel, Switzerland:
risk factors
immunology processed this record on October 21, 2016